ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.
399 Thornall Street
Edison, NJ 08837
Founded in 2013
ContraVir Pharmaceuticals Mulls Acquisitions
Apr 24 17
ContraVir Pharmaceuticals, Inc. (NasdaqCM:CTRV) is seeking acquisitions. ContraVir Pharmaceuticals announced a follow on public offering. ContraVir Pharmaceuticals intends to use the net proceeds from the sale of the securities to fund research and development activities, including ongoing clinical trials, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.
ContraVir Pharmaceuticals, Inc. Presents Data Demonstrating the Synergistic Antiviral Activity from the Combination of its Two Investigational Drugs for the Treatment of Hepatitis B Viral Infection, Tenofovir Exalidex and CRV431
Apr 22 17
ContraVir Pharmaceuticals, Inc. presented data demonstrating the synergistic antiviral activity from the combination of its two investigational drugs for the treatment of hepatitis B viral (HBV) infection, tenofovir exalidex (TXL™, formerly CMX157) a nucleotide reverse transcriptase inhibitor and CRV431, a cyclophilin inhibitor. In addition, the mode of action (MOA) of CRV431 was further defined. TXL™, a potent prodrug of the successful antiviral agent tenofovir, works by lowering infectious viral HBV DNA in the liver and blood. CRV431, a cyclophilin inhibitor, complements the activity of TXL™ by reducing levels of the hepatitis B surface antigen (HBsAg), a viral protein that is a marker of HBV infectivity and disease progression. CRV431 also impedes the binding of HBx, another key HBV protein, to cyclophilin A, an important cellular protein; together, HBx and HBsAg are considered essential to hepatitis B viral replication, disease progression, and pathogenesis of liver disease, including fibrosis and liver cancer. The inhibitory effect of CRV431 on the binding of these proteins as seen in vitro testing potentially provides the environment for the patient’s immune system to disable the HBV virus and its products.
ContraVir Pharmaceuticals, Inc. Announces New Data Demonstrating Clinical Antiviral Activity, as Well as Safety and Pharmacokinetic (Pk) Data of Tenofovir Exalidex
Apr 20 17
ContraVir Pharmaceuticals, Inc. announced new data demonstrating clinical antiviral activity, as well as safety and pharmacokinetic (PK) data of tenofovir exalidex (TXL™). TXL™ is the company’s proprietary liver targeting prodrug of the antiviral agent tenofovir for treating chronic hepatitis B virus (HBV), designed to offer equal or better HBV viral load reductions at doses lower than Viread® (TDF), a commercially available tenofovir prodrug. ContraVir is also focusing on optimizing drug delivery of TXL™ to improve bioavailability and enhance its pharmacological activity. The data were presented at The International Liver Congress™ (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL) in Amsterdam, The Netherlands. Notably, data from the presentation, ‘Pharmacokinetics, Safety and Antiviral Activity of TXL™, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects,’ was chosen to be included in the best of viral hepatitis at ILC2017 debrief recording, where Professor Fabien Zoulim and Professor Heiner Wedemeyer will provide overviews on the latest in viral hepatitis research and patient management. Dr. Tawesak Tanwandee, Associate Professor of Medicine and Head of the Division of Gastroenterology in the Department of Medicine at Siriraj Hospital, Mahidol University in Bangkok, Thailand and colleagues, conducted a trial in which they evaluated the effects of multiple ascending oral doses of TXL™ in healthy volunteers, as well as a second trial performed in HBV patients. The first trial, a Phase 1b study, enrolled 50 healthy volunteers assigned to one of five sequential, ascending TXL™ dosing cohorts (5, 10, 25, 50, and 100 mg) where participants were randomized 8:2 to receive either TXL™ or placebo for 14 days. The second Phase 2a trial evaluated the effects of multiple ascending oral doses of TXL™ (10, 25, 50, and 100 mg) in a proof-of-concept (POC) trial involving four cohorts of 12 HBV-infected subjects randomized 10:2 to receive either TXL™ or Viread® for 28 days. Interim data in the POC study have demonstrated that a 100-mg dose of TXL™ resulted in a mean HBV viral load (Log10 IU/mL, 3.63 + 1.68) (mean + SD) compared to the mean viral load from a 300-mg dose of Viread® (Log10 IU/mL, 3.75 + 1.17) after 21 days of treatment. The reduction in viral load persisted for up to one month after cessation of treatment. The data demonstrated that TXL™, at all doses tested, resulted in substantially lower systemic circulating levels of tenofovir in the blood compared to Viread®. These results demonstrate the potential for TXL™ to reduce the risk of bone- and kidney-related toxicities associated with Viread®. There were no serious adverse events (AEs) or discontinuations due to AEs, and other safety parameters (e.g., electrocardiograms, vital signs, safety laboratory results) showed no patterns, clusters, or relationship to the TXL™ dose.